Provider Portal
Provider Login
Interested in a provider account? Get started
Collection Instructions
Science and Research
Webinars
For Provider
Cutting Edge Technology
Proprietary 3Dense
microchip technology
platform with Microarrays
and Mass Spectrometry
Our Tests
Get to the root of complex
health puzzles with the most
advanced functional testing
available.
Help center
Explore our comprehensive
knowledge base
Patient navigation System
Patient Login
Make Payment
Track Kit Status
Help Center
For Patient
Collection Instructions
Simple At-home Collection
instructions and videos
Our Tests
Explore our Test menu for a
comprehensive offering of
advanced Wellness testing
Blood Draw Locations
Schedule and get your blood
drawn at a draw center or
from a mobile phlebotomist
At-home.
Technology
Cutting Edge Technology
Proprietary 3Dense
microchip technology
platform with Microarrays
and Mass Spectrometry.
Science and Research
Research featured in peer-
reviewed publications with
renowned international
institutions.
Advanced Software
Creative software solutions
to improve efficiency.
About
About Us
Our expert team that guides
our path and your Wellness.
Certifications
View our certifications,
licenses, and compliance
guidelines
Career
Join the lab tech revolution
and change the face of
health & wellness
Test Menu
Gut Health
Infections
Cardiovascular Health
Toxins
Neural Health
Nutrients
Hormones
Longevity
Autoimmune
Food Reaction
Choose a Infections Test to get started
Candida + IBS Profile
Assesses the presence of fungal overgrowth and antibody levels associated with IBS
Learn More
Tickborne Diseases Test
Tests for various tickborne diseases, including Lyme and TBRF, and co-infections of tickborne diseases
Learn More
Viral Infections Test
Measures IgG, IgA, and IgM antibody responses to seven of the most common infections associated with autoimmunity of the nervous system
Learn More
Test for Infections
An infection can be defined as an illness due to pathogens like viruses or bacteria or their toxic products. Pathogens and their toxins are transmitted to a susceptible host via an infected person, animal, or contaminated object.1 Infectious diseases result in an immense global burden that can impact public health and economies.2 Infections can be contracted through environmental sources or human contact and can wreak havoc on various body systems. If not diagnosed, infections can cause chronic inflammation, disease development, and even neurological symptoms. Prompt diagnosis and treatment can help reduce the transmission and impact of infectious diseases.
Vibrant has an Infection Panel that can readily detect the presence of various classes of microbes, revealing the root cause of symptoms.
Infections and longevity

Infections play a role in longevity. It has been hypothesized that exposure to infectious diseases during the early stages of life can increase the risk of mortality.3 Infections cause inflammatory immune reactions and chronic inflammation can increase the risk of atherosclerosis, stroke, cardiovascular diseases, and mortality. Several studies have associated the chronic inflammation caused due to early-life infections with cardiovascular diseases and increased middle-aged mortality.4

Clinical Consultants
Dr. Monica E. Embers
Dr. Patrick Meyer
Patrick M Meyer Sauteur, MD, Ph.D. is part of the University Children's Hospital, Zurich, Switzerland. His research focuses on pneumonia in children, mycoplasma, Lyme disease, and acute monocutaneous reactions to infections. Mycoplasma pneumonia and Lyme disease are serious infections that can be considered endemic in the USA. Understanding these diseases can help improve diagnostic methods and treatment for the same. Dr. Meyer has worked on and published several papers on Mycoplasma pneumonia.6 Furthermore, he has collaborated with Vibrant America in studying Lyme disease.
Expert opinions 
Dr. Niaz Banaei
Niaz Banaei, MD is a Professor of Pathology and Medicine at Stanford University and is the Director of the Stanford Clinical Microbiology Fellowship and Stanford Global Health Diagnostics Fellowship. He is also the associate program director for the Clinical Pathology training program. His research focuses on the development, assessment, improvement, and clinical impact of novel infectious diseases diagnostics, and immunopathogenesis of M. tuberculosis. Dr. Banaei has worked on and published papers on several infectious diseases including but not limited to Sars-Cov-2, M. tuberculosis, etc.7
Our Publications, Patents, & Clinical Trials
Antibody Profiling and Prevalence in the US population during the SARS-CoV2 Pandemic
In the study ‘Antibody Profiling and Prevalence in the US population during the SARS-CoV2 Pandemic’ we employed our microarray technology to detect Sars-Cov-2. The method had high sensitivity and specificity, scalability, high fidelity, and reliability which will be critical to the control of the current pandemic.9
Serology profile and effects of influenza vaccination on COVID-19-positive symptomatic and asymptomatic patients’
In our publication ‘Serology profile and effects of influenza vaccination on COVID-19-positive symptomatic and asymptomatic patients’ we reported that the influenza vaccine does not provide protection against Sars-Cov-2 but may attenuate symptom severity.10 
An ultra-high‑density protein microarray for high throughput single‑tier serological detection of Lyme disease
In the study 'An ultra‑high‑density protein microarray for high throughput single‑tier serological detection of Lyme disease’ we demonstrated that the Lyme Immunochip is a valid alternative to standard two-tiered testing, with the capability to characterize the antibody profile of Lyme disease patients with enhanced accuracy and reduced turnaround time. Our microarray has the potential to be an accurate, rapid, economical, and universal diagnostic testing platform.11
A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients
In the publication ‘A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients’ we used our microarray technology to detect antibodies against Sars-Cov-2.12
Reference
1.
Naghavi, M., Wang, H., Lozano, R., Davis, A., Liang, X., & Zhou, M. (2015). GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 385(9963), 117-171.
2.
Van Seventer, J. M., & Hochberg, N. S. (2017). Principles of infectious diseases: transmission, diagnosis, prevention, and control. International encyclopedia of public health, 22.
3.
Finch, C. E. (2010). Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition. Proc Natl Acad Sci U S A, 107(Suppl 1(Suppl 1)), 1718-24.
4.
Hayward, A. D., Rigby, F. L., & Lummaa, V. (2016). Early-life disease exposure and associations with adult survival, cause of death, and reproductive success in preindustrial humans. Proc Natl Acad Sci U S A, 113(32), 8951–8956.
5.
Curtis, M. W., Krishnavajhala, A., Kneubehl, A. R., Embers, M. E., Gettings, J. R., Yabsley, M. J., & Lopez, J. E. (2022). Characterization of Immunological Responses to Borrelia Immunogenic Protein A (BipA), a Species-Specific Antigen for North American Tick-Borne Relapsing Fever. Microbiol Spectr, 10(3), e01722-21.
6.
Meyer Sauteur, P. M., Unger, W. W., Nadal, D., Berger, C., Vink, C., & van Rossum, A. M. (2016). Infection with and carriage of Mycoplasma pneumoniae in children. Frontiers in microbiology, 7, 329.
7.
Murugesan, K., Jagannathan, P., Altamirano, J., Maldonado, Y. A., Bonilla, H. F., Jacobson, K. B., ... & Banaei, N. (2021). Long term accuracy of SARS-CoV-2 interferon-γ release assay and its application in household investigation. medRxiv, 2021-09.
8.
Laksanasopin, T., Guo, T. W., Nayak, S., Sridhara, A. A., Xie, S., Olowookere, O. O., ... & Sia, S. K. (2015). A smartphone dongle for diagnosis of infectious diseases at the point of care. Science translational medicine, 7(273), 273re1-273re1.
9.
Krishnamurthy, H. K., Jayaraman, V., Krishna, K., Rajasekaran, K. E., Wang, T., Bei, K., ... & Murray, J. A. (2020). Antibody profiling and prevalence in US patients during the SARS-CoV2 pandemic. PloS one, 15(11), e0242655.
10.
Grossberg, A. N., Koza, L. A., Ledreux, A., Prusmack, C., Krishnamurthy, H. K., Jayaraman, V., ... & Linseman, D. A. (2020). Serology profile and effects of influenza vaccination on COVID-19-positive symptomatic and asymptomatic patients.
11.
Jayaraman, V., Krishna, K., Yang, Y., Rajasekaran, K. J., Ou, Y., Wang, T., ... & Green, D. A. (2020). An ultra-high-density protein microarray for high throughput single-tier serological detection of Lyme disease. Scientific Reports, 10(1), 1-10.
12.
Grossberg, A. N., Koza, L. A., Ledreux, A., Prusmack, C., Krishnamurthy, H. K., Jayaraman, V., ... & Linseman, D. A. (2021). A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. Nature communications, 12(1), 740.
One lab one box
Intuitive interactive reporting
Subscribe to our newsletter !
Get the latest product and company updates
VW logo
Address
3521 Leonard Ct, Santa Clara, CA 95054
Solutions
For Patients
For Providers
Our Tests
Company
About Us
Careers
Contact Us
Resources
Vibrant Functional Academy
Webinar
Science and Research
Support
Announcements
Help Center
FAQ
Terms of Use
Privacy Policy
Testing Policy
Billing Information
Disclaimer
© 2023 Vibrant lab All right reserved